Midora (Amisulpride)

Amisulpride selectively blocks dopamine D2 and D3 receptors, especially in limbic areas of the brain. This antagonism reduces excessive dopaminergic activity that contributes to psychotic and depressive symptoms, thereby stabilising mood and thought processes.

The appropriate dose of Midora is determined individually by a qualified prescriber based on the patient’s clinical condition, response, and tolerability. Dosage adjustments may be needed for special populations such as the elderly or those with renal impairment.

Midora should only be used during pregnancy or lactation if the potential therapeutic benefit outweighs the possible risk to the fetus or infant. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss the risks and alternatives with their healthcare provider.

To request Midora, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Midora (amisulpride) is a benzamide antipsychotic that primarily blocks D2/D3 receptors, offering a distinct side‑effect profile compared with typical antipsychotics and some atypicals like risperidone. It may cause fewer extrapyramidal symptoms at low doses but can raise prolactin levels, so choice depends on individual patient factors.

Midora should be stored at room temperature, below 25 °C, in its original container. Keep the product away from moisture, direct sunlight and excessive heat to maintain its stability and potency throughout its shelf life.

Midora is taken orally, usually as a tablet, with or without food as directed by the prescribing clinician. The exact timing and frequency are individualized, and patients should follow the prescriber’s instructions for optimal therapeutic effect.

The most serious risks include neuroleptic malignant syndrome, severe extrapyramidal reactions such as tardive dyskinesia, and QT‑interval prolongation that can lead to cardiac arrhythmias. Prompt medical attention is required if symptoms like high fever, muscle rigidity, irregular heartbeat or severe movement disorders occur.

Midora is contraindicated in patients with known hypersensitivity to amisulpride or any component of the formulation, and it should be used with caution in individuals with severe cardiac disease, uncontrolled epilepsy, or a history of neuroleptic malignant syndrome. Pregnant or breastfeeding women should only use it when clearly indicated by a physician.